Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Hong-Tao Jiang, Wei Li, Biao Zhang, Qiang Gong & Hai-Ling Qie. (2021) Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study. International Journal of General Medicine 14, pages 7625-7637.
Read now
Read now
Wenxia Hu, Bin Li, Nan Geng, Xin He, Hui Ge, Ping Wang & Cuimin Ding. (2021) Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study. International Journal of General Medicine 14, pages 2703-2714.
Read now
Read now
Zi-Zheng Song, Li-Fen Zhao, Jing Zuo, Zhi-Song Fan, Long Wang & Yu-Dong Wang. (2020) Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism. OncoTargets and Therapy 13, pages 603-613.
Read now
Read now
Xinran Ma, Ling Li, Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li & Mingzhi Zhang. (2020) Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. Drug Design, Development and Therapy 14, pages 275-284.
Read now
Read now
Peng-Fei Song, Ning Xu & Qin Li. (2020) Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions. Cancer Management and Research 12, pages 11133-11143.
Read now
Read now
Jian-De Cheng, Li-Xun Chai, Zhi-Ping Zhao, Yan-Yan Hao & Shuo Li. (2020) Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer Management and Research 12, pages 5641-5650.
Read now
Read now
XueJiao Yang, ZhenYu Hou, KeYun Zhu, Su Zhang, XiaoYing Gu, ZhiWei Wang, Han Mu, HongYuan Zhou, Ping Chen, XiaoLin Zhu, YunLong Cui, Qiang Li, HuiKai Li & Ti Zhang. (2020) Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma. Cancer Management and Research 12, pages 3163-3173.
Read now
Read now
Ruijuan Zhang, Qianyun Yu, Wenqiang Lu, Jun Shen, Dongqing Zhou, Yingjue Wang, Shurong Gao & Zhijun Wang. (2019) Grape seed procyanidin B2 promotes the autophagy and apoptosis in colorectal cancer cells via regulating PI3K/Akt signaling pathway. OncoTargets and Therapy 12, pages 4109-4118.
Read now
Read now
Articles from other publishers (9)
Kaidi Le, Min Liu, Yinglin Ma, Jiaqing Yan, Ying Li & Guohui Li. (2024) Evaluation of Apatinib-Related Hypertension and Identification of Clinical Risk Factors. Journal of Clinical Pharmacy and Therapeutics 2024, pages 1-8.
Crossref
Crossref
Wenxian Wang, Lan Shao, Yibing Xu, Zhengbo Song, Guangyuan Lou, Yiping Zhang & Ming Chen. (2022) Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. BMC Pulmonary Medicine 22:1.
Crossref
Crossref
Nicholas Camarda, Richard Travers, Vicky K. Yang, Cheryl London & Iris Z. Jaffe. (2022) VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. Current Oncology Reports 24:4, pages 463-474.
Crossref
Crossref
Yonghui Li, Zhenqing Sun, Wei Sun, Haibo Wang & Jinchi Zu. (2022) Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study. Clinical Medicine Insights: Oncology 16, pages 117955492110671.
Crossref
Crossref
Zhichao Tian, Xiaohui Niu & Weitao Yao. (2021) Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. Frontiers in Oncology 11.
Crossref
Crossref
Jing Ni, Xianzhong Cheng, Rui Zhou, Qian Zhao, Xia Xu, Wenwen Guo, Hongyuan Gu, Chen Chen & Xiaoxiang Chen. (2021) Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor. Frontiers in Oncology 11.
Crossref
Crossref
Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li & Zhian Liu. (2021)
Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (
SCC
): A post hoc analysis of the
ALTER0303
trial
. Thoracic Cancer 12:17, pages 2345-2351.
Crossref
Crossref
Zhen Yan, Yuan‑Yuan Gu, Xiao‑Di Hu, Qun Zhao, Hai‑Li Kang, Miao Wang, Wei Duan & Yin Guan. (2020) Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncology Letters 20:3, pages 3035-3045.
Crossref
Crossref
Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang & Xin Sun. (2020) The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. International Journal of Clinical Oncology 25:6, pages 1195-1205.
Crossref
Crossref